Calypte Only Company with Full Menu of Tests.

die erfolgsrechnung!! studiere die mal ganz genau joelu!!  

du für ne weile ausm verkehr gezogen bist, weil de rumsuchst. nein ich habe nicht verkauft, also habe ich weder verlust noch gewinn du stratege. solltest dich mal ein wenig mit dem chargon der börse auseinanderstzen. so und nun überlaß ich dich wieder deinen selbstgesprächen. viel spaß. ;O)  

wenn einer bei einem kurs von 0,53 noch 30% im minus oder etwas bzw. weniger. dann kannst du "auf 100" oder "in 100" rechnen, wenn du überhaupt weißt, was das ist. ich habe die variante gerechnet, mit der weniger verlust anfällt und habe dann sogar "nur" 25% genommen

nicht auszuschliessen, dass micha sogar einen durchschnittskurs von über 0,70$ hat...genau weiß man es nicht.

aber eines, dann kann ich dir mit sicherheit sagen...und auch micha.

micha belügt sich und andere, wie die meisten sich hier gegenseitig belügen und noch selbst belügen, um mit ihren caly-verlusten schlafen zu können.

micha, sag: bist du ein unehelicher stiefbruder von kade?

--------------------------------------------------
677. du bist selten dämlich junge. hab doch gewußt, das   Mischa   29.06.05 17:29  

du für ne weile ausm verkehr gezogen bist, weil de rumsuchst. nein ich habe nicht verkauft, also habe ich weder verlust noch gewinn du stratege. solltest dich mal ein wenig mit dem chargon der börse auseinanderstzen. so und nun überlaß ich dich wieder deinen selbstgesprächen. viel spaß. ;O)  
--------------------------------------------------

das problem ist, wenn man eure lügen dann aufdeckt, werdet ihr ganz schnell zickig und wollt den stachel der wahrheit nicht spüren...

soso micha, da hast du also keinen verlust gemacht mit "be aware-calypte"....

"...nein ich habe nicht verkauft, also habe ich weder verlust noch gewinn du stratege. solltest dich mal ein wenig mit dem chargon der börse auseinanderstzen..."

das muß ich mir nochmal auf der zunge zergehen lassen, du hast also keinen verlust gemacht, weil du nicht verkauft hast...ahhhhhhhhhh ......dann hat man also keinen verlust...gut....

muahahhahahahahaaha.............


weißt du was, dann habe ich also rein theoretisch auch keinen verlust mit augrid gemacht, weil iich sie nicht verkauft habe, oder was????????? auch wenn sie nur noch einen buchwert von 80$ haben???????????? prust!!!!!!!!!!!!!!!!

nein junge, ich bin so ehrlich und lüge mir nicht in die tasche, dass ich keinen verlust gemacht habe.

komm junge, geh wieder mit murmeln spielen und erzähle den anderen im sandkasten "deine börsenweisheiten"....

unglaublich...ich dachte du wärest erwachsen und würdest versicherungen für die volksfürsorge verkaufen?
 

kennst.
aus nondiskussionsgründen gebe ich dir recht und ja: alle caly-aktionäre sind lügner! LOL
 

dr. udo bromme zitieren:


"
Never argue with an idiot -- they drag you down to their level, then beat you with experience."


...und tschüßßßßßßßßßß........  

hoffe diw qualität des threads steigt jetzt wieder.
bin momentan voll fett bei EPYH drinn. habe aber caly auf der hotwatchlist & bin immer noch ready to jump over wenn da wirklich was kommen sollte....  

dann werde ich auf einen kurzen zock einsteigen...


die letzten trades:



Time & Sales  
Price Size Time
0.16 300 15:59:16
0.16 2000 15:59:16
0.16 25000 15:05:43
0.16 10000 15:01:37
0.16 5600 14:35:52
0.17 10000 13:46:29
0.17 10000 13:46:23
0.16 6400 13:25:48
0.16 500 13:18:19
0.17 10000 13:17:17
0.17 40000 13:17:03
0.17 39400 13:16:58
0.17 5000 12:54:57
0.17 8700 12:39:52
0.16 500 12:33:28
0.16 600 11:40:02
0.17 3100 11:39:52
0.17 1900 11:39:51
0.16 100 11:33:42
0.16 7000 11:30:19
0.16 10000 11:26:53
0.16 15000 11:16:34
0.16 2000 11:10:59
0.16 2600 11:08:56
0.16 2000 11:08:44
0.16 2000 11:08:21
0.16 9800 11:08:08
0.16 2200 11:08:07
0.16 6000 11:08:07
0.16 2000 11:08:07
 

Support/Resistance
Type Value Conf.
resist. 0.40 2
resist. 0.33 12
resist. 0.32 7
resist. 0.30 7
resist. 0.28 3
resist. 0.27 10
resist. 0.25 2
resist. 0.24 4
resist. 0.23 16
resist. 0.22 9
resist. 0.21 4
resist. 0.20 27
resist. 0.19 3
resist. 0.18 2
 

Time & Sales  
Price Size Time
0.16 700 06/30
0.16 700 06/30
0.16 2300 06/30
0.16 1000 06/30
0.17 200 06/30
0.16 6100 06/30
0.16 500 06/30
0.16 600 06/30
0.16 9700 06/30
0.16 9700 06/30
0.16 10900 06/30
0.16 2000 06/30
0.16 2000 06/30
0.16 20100 06/30
0.16 9900 06/30
0.16 104800 06/30
0.17 700 06/30
0.16 7000 06/30
0.16 1400 06/30
0.16 100000 06/30
0.16 9000 06/30
0.16 500 06/30
0.16 100 06/30
0.17 30000 06/30
0.17 25000 06/30
0.17 25000 06/30
0.17 2500 06/30
0.17 10000 06/30
0.17 2700 06/30
0.16 2000 06/30
 

Support/Resistance
Type Value Conf.
resist. 0.40 2
resist. 0.33 12
resist. 0.32 7
resist. 0.30 7
resist. 0.28 3
resist. 0.27 10
resist. 0.24 3
resist. 0.23 16
resist. 0.22 10
resist. 0.21 4
resist. 0.20 26
resist. 0.19 4
resist. 0.17 2
 

 

TRIB und steht unverändert bei 6,48 oder 1,62$ vor dem splitt.

und wo steht caly vor dem splitt??????

0,16 : 30 = 0,0053???  

Uganda Survives Aids Funds Cut


   
 
 


The Monitor (Kampala)

July 1, 2005
Posted to the web July 1, 2005

Charles M. Mpagi & Peter Nyanzi
Kampala

CLAIMS by HIV/Aids activists that funds from the Global Fund on Aids were being diverted to support political activities, almost led to the withdrawal of the funds, a top official in the Ministry of Health has said.

The revelation comes on the heels of a new aid package announced by US President Mr George Bush yesterday, to support the fight against Malaria in the country.

 
The Director General of Health Services, Prof. Francis Omaswa, told journalists at the weekly cabinet press briefing on Thursday that he had to offer explanations to the Fund headquarters in Geneva following the reports.

Omaswa chairs one of the international committees of the multi-billion dollar Global Fund on Aids, Tuberculosis and Malaria.

"There were threats to even cancel the global fund for Uganda. I had to deal with these questions on telephone. It has caused a lot of upheaval," Omaswa said.

Daily Monitor reported on June 25, that HIV/Aids activists had petitioned the chairman of the Parliamentary Committee on HIV/Aids, Dr Elioda Tumwesigye, demanding for accountability and transparency in the management of the funds.

A leading HIV/Aids activist, Maj. Rubaramira Ruranga, said government was plotting to use the funds to sponsor its political activities especially the third term campaign.

But the saga took a new twist on Sunday when the Presidential Assistant on Legal Affairs, Mr Fox Odoi, returned the fire on a KFM radio talk show, saying Ruranga had failed to account for a Shs53 million advance from the Global Fund.

Omaswa said the reports had caused concern across the World.

The Minister of Health, Maj. Gen. Jim Muhwezi, said, the fund in Uganda was being managed in a transparent manner. "No funds have been diverted to support political activities in the country and there has been no attempt to shift the funds as alleged in the media," he said.

Relevant Links

East Africa
HIV-Aids and STDs
Crime and Corruption
International Organizations and Africa
Uganda



Muhwezi said grant contracts worth $201 million (Shs351 billion) had been signed for the next two years, with provision for an additional $169 million over the next three to five years. Only $45 million (about Shs787 million) had been disbursed over the last 13 months.

A member of the Country Coordinating Mechanism (CCM) who declined to be named said it would be disastrous if the government tampered with the inclusive structure of managing the Global Fund.




http://allafrica.com/stories/200507010920.html  

Shareholder Meeting beginnen ; )

Auf neue Höhen mit Calypte

Gruß

C.O  

Einstiegspunkt oder noch warten?


Servus
boersenjunky

-- reich wird man nicht durch das, was man verdient, sondern durch das, was man nicht ausgibt.--  

More People Must Know HIV Status To Further Progress Global Fight Against HIV/AIDS, Tobias Says
[Jul 01, 2005]
The number of people who know their HIV status must "dramatically increas[e]" for the global fight against HIV/AIDS to "further progress," U.S. Ambassador Randall Tobias, head of the State Department Office of the U.S. Global AIDS Coordinator, writes in a Miami Herald opinion piece. In order to reach the President's Emergency Plan for AIDS Relief's five-year goal of supporting antiretroviral treatment for two million HIV-positive people in 15 hard-hit countries, the government estimates that 100 million more people must undergo HIV testing, Tobias says, adding that only people who know they are HIV-positive seek treatment and are able to "take steps for prevention." Integrating voluntary testing and counseling into routine health care, counseling and testing couples, offering testing to the families of HIV-positive people, and implementing mobile-unit and door-to-door testing are some of the ways the United States and host nations are working together to achieve PEPFAR's goal, Tobias says. "The challenge is daunting," but PEPFAR and its partners are "facing it with ingenuity and passion" and are "working urgently to make counseling and testing widely available," he says.


Gruß

C.O

 

ich würde noch warten mit dem einsteigen. ihr seht erst noch die 0,12 bzw. 0,11$, dann lohnt sich ein 20-30%-zock!

broker: was soll bei dem meeting herausgekommen sein? ein aktienrückkauf bestimmt nicht! eher die ausgabe weitere aktien.

auf zu neuen untiefen!!!!


für juni hatte ich euch schlußkurse unter 0,20$ versprochen....

für juli verspreche ich euch das touchieren der 0,12$...

und broker: von den 5$ bist du im august so weit entfernt, wie der nordpol vom südpol.

das solltest du endlich mal akzeptieren und mal die wahrheit zulassen, oder bist du so gestrickt wie kade?

einfach: den riesenfehler einsehen und lernen...  

http://mm.dfilm.com/mm2s/mm_route.php?id=2475726


Gruß

C.O  

Calypte Announces Distribution Agreements in Eight African Countries
      Regulatory Trials to Begin in Three Additional African Countries
PLEASANTON, Calif., July 5 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it has executed distribution agreements with two distributors for the marketing and sale of its Aware(TM) rapid HIV antibody tests in eight countries in Sub-Saharan Africa. According to the terms of these agreements, Lily-Max (Pty) Ltd. based in Kampala, Uganda will retain exclusive distribution rights in the Republic of Uganda, Rwanda, Burundi and Democratic Republic of Congo; Bioweb (Pty) Ltd. will retain exclusive distribution rights in Kenya, Tanzania, Cameroon, and Chad.

Calypte previously announced that it received a positive recommendation that the Uganda National Drug Authority grant approval for the importation of the Aware(TM) rapid HIV 1/2 Antibody Tests. Subsequent to this recommendation, Calypte received its first purchase order from Lily-Max Ltd., its Ugandan distributor, and will complete shipment of this order out of its Thailand manufacturing facility.

Dr. J. Richard George, President and CEO of Calypte said, "We're making great progress in moving our strategy forward in the African continent by building what we believe to be a solid foundation that leverages the strengths and resources of these well-abled distributors. We have expanded our representation from two sub-Saharan countries to ten in total, and we will be aggressively pursuing sales as the regulatory process is completed in the appropriate territories. We expect to complete regulatory trials in at least four countries during the second half of this year."

Mr. George M. Kabiri, Director of Lily-Max said, "I am confident that the collaboration between Lily-Max and Calypte Biomedical will yield a very successful venture for the benefit of both companies, and the territory we represent. We are very excited that, with the initial order made for the products, Lily-Max will be able to stock and supply the entire range of Calypte tests to our respective territories."

Liam Kelly and Kevin Ward, co-Directors of Bioweb, stated "We are most excited to be part of Calypte's roll-out campaign in Africa, and look forward to partnering with them in our territories. These are countries in which we have worked closely with our own distributors in building up a successful sales track record. We firmly believe we can now build on these relationships to pursue sales of Calypte products."

Additionally, regulatory trials have been initiated in Zimbabwe for Aware(TM) BSP, a rapid test for HIV antibodies using whole blood, serum, and plasma samples. Calypte has also signed clinical agreements to begin trials for all three Aware(TM) rapid tests in Kenya and Cameroon. These regulatory trials are scheduled to begin this month, and Calypte will be working closely with both Lily-Max and Bioweb to develop a regulatory strategy for the other six countries in their territories.

Calypte has developed three twenty-minute rapid tests for the detection of antibodies to HIV-1 and HIV-2 viruses - the viruses that cause AIDS. Each of the three tests is designed for use on a different sample type: Aware(TM) BSP uses whole blood, serum or plasma samples; Aware(TM) OMT uses oral fluid samples, and Aware(TM) U uses urine samples.

About Calypte Biomedical:

Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.

Contact: Company, Richard George, President and CEO of Calypte Biomedical Corporation, +1-925-730-7200 or email, rgeorge@calypte.com or Investor Relations, Tim Clemensen of Rubenstein Investor Relations, +1-212-843-9337 or email, tclemensen@rubensteinir.com

SOURCE  Calypte Biomedical
   -0-                             07/05/2005
   /Contact: Company, Richard George, President and CEO of Calypte Biomedical
Corporation, +1-925-730-7200 or email, rgeorge@calypte.com, or Investor
Relations, Tim Clemensen of Rubenstein Investor Relations, +1-212-843-9337 or
email, tclemensen@rubensteinir.com/
   /Web site:  http://www.calypte.com/
   (HIV)

CO:  Calypte Biomedical Corporation; Lily-Max (Pty) Ltd.; Bioweb (Pty) Ltd.
ST:  California, Uganda, Rwanda, Burundi, Democratic Republic of Congo
IN:  HEA MTC
SU:  CON

NM-JS
-- CLTU501 --
9423 07/05/2005 10:11 EDT http://www.prnewswire.com


Gruß

C.O  

 

nochmal ein kleines aufbäumen?

los kommt, steigt ein, wer noch nicht drin ist...

das sit doch wieder die typische masche von caly...wo bleiben die umsätze

von den distributionsabkommen hatten wir schon reichlich in der vergangenheit. gebracht hat es außer rückläufigen umsätzen nichts...

die spitze habt ihr mit 0,21 mal wieder gesehen...  

Support/Resistance
Type Value Conf.
resist. 0.40 2
resist. 0.33 12
resist. 0.32 3
resist. 0.30 7
resist. 0.28 3
resist. 0.27 10
resist. 0.24 2
resist. 0.23 15
resist. 0.22 10
resist. 0.21 5
resist. 0.20 26
resist. 0.19 4
resist. 0.18 2


broker, was ist mit 5$ im august....na gut, sind wir nicht so hart, was ist mit 0,50$ im august?

bollerwagen anstatt porsche? oder nicht mal bollerwagen?  

Support/Resistance
Type Value Conf.
resist. 0.40 2
resist. 0.33 12
resist. 0.31 2
resist. 0.30 7
resist. 0.28 3
resist. 0.27 10
resist. 0.24 2
resist. 0.23 15
resist. 0.22 9
resist. 0.21 6
resist. 0.20 26
supp 0.19 5
supp 0.18 2


na, eine unterstützung bei 0,18 und 0,19...das ist doch schon mal was...muhahahahahaa  

Time & Sales  
Price Size Time
0.20 17100 15:58:00
0.20 900 15:56:22
0.20 600 15:52:33
0.19 9000 15:52:13
0.19 10000 15:52:02
0.20 10000 15:44:52
0.19 3000 15:43:39
0.19 10000 15:42:48
0.20 600 15:42:46
0.19 10000 15:42:38
0.19 5000 15:42:36
0.19 5000 15:42:32
0.19 45000 15:42:28
0.19 45000 15:42:27
0.19 15000 15:40:11
0.19 13000 15:40:05
0.19 100 15:39:25
0.19 20000 15:36:35
0.19 20000 15:29:01
0.19 50000 15:28:54
0.19 10000 15:16:53
0.20 1400 15:16:50
0.20 10000 15:11:41
0.20 100 14:53:46
0.20 500 14:50:06
0.20 2000 14:47:19
0.20 400 14:44:26
0.20 500 14:37:52
0.20 3000 14:36:48
0.20 200 14:29:19
 

By: roy_hinkley  
05 Jul 2005, 10:42 AM EDT
Msg. 67706 of 67711
(This msg. is a reply to 67705 by newgreenpaper.)
Jump to msg. #  
Here comes the Richard George pump. First sale is to the Afican distibutor. Of course no mention of how big or if distributor has sold it to anyone, or of the costs, or sales price, profit etc.

What happened to the we won't report it until we are paid and can give all the details as in the incidence tests last fall. That don't sell much stock does it?

Last sale to a Chinese distributor was for 3 million tests and only 300,000 were ever delivered and I don't know if any of those were even sold.

Sales, Money in the bank and profit. Lets see it boys...

BTW how did dilution Thursday at the annual stockholders meeting go anyway?